MBIO Valuation

Mustang Bio Inc

Add to Watchlist

Advanced Chart

1.210

0(0.000%)1D

MBIO Relative Valuation

MBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MBIO is overvalued; if below, it's undervalued.

Historical Valuation

Mustang Bio Inc (MBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 1.25 is considered Fairly compared with the five-year average of -2.06. The fair price of Mustang Bio Inc (MBIO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.23

Fair

-0.07

Trailing

Forward

0.47

EV/EBITDA

Mustang Bio Inc. (MBIO) has a current EV/EBITDA of 0.47. The 5-year average EV/EBITDA is -0.33. The thresholds are as follows: Strongly Undervalued below -2.26, Undervalued between -2.26 and -1.29, Fairly Valued between 0.64 and -1.29, Overvalued between 0.64 and 1.60, and Strongly Overvalued above 1.60. The current Forward EV/EBITDA of 0.47 falls within the Historic Trend Line -Fairly Valued range.

0.47

EV/EBIT

Mustang Bio Inc. (MBIO) has a current EV/EBIT of 0.47. The 5-year average EV/EBIT is -0.70. The thresholds are as follows: Strongly Undervalued below -3.28, Undervalued between -3.28 and -1.99, Fairly Valued between 0.59 and -1.99, Overvalued between 0.59 and 1.87, and Strongly Overvalued above 1.87. The current Forward EV/EBIT of 0.47 falls within the Historic Trend Line -Fairly Valued range.

1.21

Mustang Bio Inc. (MBIO) has a current PS of 1.21. The 5-year average PS is 0.01. The thresholds are as follows: Strongly Undervalued below -0.26, Undervalued between -0.26 and -0.12, Fairly Valued between 0.15 and -0.12, Overvalued between 0.15 and 0.29, and Strongly Overvalued above 0.29. The current Forward PS of 1.21 falls within the Strongly Overvalued range.

-0.18

P/OCF

Mustang Bio Inc. (MBIO) has a current P/OCF of -0.18. The 5-year average P/OCF is -1.43. The thresholds are as follows: Strongly Undervalued below -5.07, Undervalued between -5.07 and -3.25, Fairly Valued between 0.39 and -3.25, Overvalued between 0.39 and 2.21, and Strongly Overvalued above 2.21. The current Forward P/OCF of -0.18 falls within the Historic Trend Line -Fairly Valued range.

-0.18

P/FCF

Mustang Bio Inc. (MBIO) has a current P/FCF of -0.18. The 5-year average P/FCF is -1.38. The thresholds are as follows: Strongly Undervalued below -4.87, Undervalued between -4.87 and -3.13, Fairly Valued between 0.36 and -3.13, Overvalued between 0.36 and 2.11, and Strongly Overvalued above 2.11. The current Forward P/FCF of -0.18 falls within the Historic Trend Line -Fairly Valued range.

Mustang Bio Inc (MBIO) has a current Price-to-Book (P/B) ratio of 0.93. Compared to its 3-year average P/B ratio of 8.40 , the current P/B ratio is approximately -88.88% higher. Relative to its 5-year average P/B ratio of 5.75, the current P/B ratio is about -83.76% higher. Mustang Bio Inc (MBIO) has a Forward Free Cash Flow (FCF) yield of approximately -0.61%. Compared to its 3-year average FCF yield of -272.03%, the current FCF yield is approximately -99.78% lower. Relative to its 5-year average FCF yield of -180.13% , the current FCF yield is about -99.66% lower.

0.90

P/B

Median3y

8.40

Median5y

5.75

-0.63

FCF Yield

Median3y

-272.03

Median5y

-180.13

Competitors Valuation Multiple

The average P/S ratio for MBIO's competitors is 3.25, providing a benchmark for relative valuation. Mustang Bio Inc Corp (MBIO) exhibits a P/S ratio of 1.21, which is -62.81% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Addex Therapeutics Ltd

Bolt Biotherapeutics Inc

Silexion Therapeutics Corp

2.91

8.97M

VYNE.O

Vyne Therapeutics Inc

0.35

39.67%

12.29M

Performance Decomposition

Market capitalization of MBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MBIO in the past 1 year is driven by Unknown.